Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
absent, accelerated, accredited, Addressing, admission, affiliate, affiliated, aimed, Alexion, ancillary, anniversary, APA, assumed, assuming, automatically, BCR, BID, bronchial, cast, Celcuity, chloride, Committee, companion, comprise, conclusion, confirm, confirmatory, convened, Conversely, conversion, creation, customary, deep, diagnosed, diffuse, dissolution, dividend, DLBCL, driver, dual, durable, engine, epithelial, equal, equipment, equivalent, exemption, exhaled, expedited, expiratory, faith, fault, FeNO, fractional, freely, greatest, holder, HutchMed, ibrutinib, IDMC, image, inflammatory, intermediate, involuntary, irreversible, issuable, Japan, junior, Karyopharm, KEAP, leaving, led, lethality, linear, lymphoma, macroglobulinemia, marker, meaningful, mg, Millennium, mitigate, mivavotinib, month, morbidity, mortality, mutant, mutual, NHL, nonsense, Notably, organizational, paralog, pharmacodynamic, plasma, pooled, poorer, proportionally, radiographic, rapalog, rapid, rational, reclassify, redeem, redefine, redemption, referenced, regular, resale, rescind, sapanisertib, Secretary, settlement, signaling, spectrum, subset, subtype, surrogate, Sweat, SYK, synthetic, thirty, thought, timeframe, TORC, transmembrane, Trikafta, unblinded, unblinding, underserved, unselected, upstream, venetoclax, verify, verity, virtue, Waldenstrom, wholly, winding, xenograft, yearly
Removed:
activating, activation, adenocarcinoma, allosteric, AstraZeneca, Bayer, block, blocking, Boehringer, cabozantinib, carboplatin, carcinoma, Celgene, clear, collectability, colorectal, differentiate, ductal, Eisai, Eli, fundamental, GlaxoSmithKline, glutamine, GmbH, grow, incidence, inferior, Ingelheim, internally, KGaA, Lilly, meaningfully, Merck, metabolically, Nektar, nutrient, palbociclib, pancreatic, PDAC, pembrolizumab, pemetrexed, Pfizer, Pharma, pioneering, plc, preferentially, reimbursable, renal, Roche, SA, Squibb, targeting, uncontrolled, underwriting, unique
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view